Authors
Ji Hyun Kim, Kyung Hee Han, Eun Young Park, Eun Taeg Kim, Eun Jeong Kim, David SP Tan, Jung-Yun Lee, Sang-Yoon Park, Christina Fotopoulou, Myong Cheol Lim
Publication date
2024/8/1
Source
Gynecologic Oncology
Volume
187
Pages
85-91
Publisher
Academic Press
Description
Background
The combination of immune checkpoint inhibitors (ICIs) and platinum-based chemotherapy has emerged as a highly promising primary option for advanced or recurrent endometrial cancer (EC). The study aimed to evaluate treatment efficacy of ICIs with cytotoxic chemotherapy in EC.
Methods
We conducted a comprehensive review of randomized controlled trials up to November 11, 2023, focusing on immunotherapy combined with chemotherapy versus chemotherapy alone for EC. The primary endpoint was the pooled hazard ratio (HR), which was further analyzed across subgroups based on mismatch repair (MMR) status, race, histology, and programmed death-ligand 1 (PD-L1) status. The protocol was registered in PROSPERO (CRD42023475669).
Findings
Four trials with 2335 patients were analyzed. ICIs with chemotherapy significantly prolonged progression-free survival (PFS) (HR, 0.70; 95% CI …
Scholar articles
JH Kim, KH Han, EY Park, ET Kim, EJ Kim, DSP Tan… - Gynecologic Oncology, 2024